Objectives This study aimed to update and validate a prediction rule for respiratory syncytial virus (RSV) hospitalization in preterm infants 33–35 weeks gestational age (WGA). Study Design The RISK study consisted of 2 multicenter prospective birth cohorts in 41 hospitals. Risk factors were assessed at birth among healthy preterm infants 33–35 WGA. All hospitalizations for respiratory tract infection were screened for proven RSV infection by immunofluorescence or polymerase chain reaction. Multivariate logistic regression analysis was used to update an existing prediction model in the derivation cohort (n = 1,227). In the validation cohort (n = 1,194), predicted versus actual RSV hospitalization rates were compared to determine validity of the model. Results RSV hospitalization risk in both cohorts was comparable (5.7% versus 4.9%). In the derivation cohort, a prediction rule to determine probability of RSV hospitalization was developed using 4 predictors: family atopy (OR 1.9; 95%CI, 1.1–3.2), birth period (OR 2.6; 1.6–4.2), breastfeeding (OR 1.7; 1.0–2.7) and siblings or daycare attendance (OR 4.7; 1.7–13.1). The model showed good discrimination (c-statistic 0.703; 0.64–0.76, 0.702 after bootstrapping). External validation showed good discrimination and calibration (c-statistic 0.678; 0.61–0.74). Conclusions Our prospectively validated prediction rule identifies infants at increased RSV hospitalization risk, who may benefit from targeted preventive interventions. This prediction rule can facilitate country-specific, cost-effective use of RSV prophylaxis in late preterm infants.
References
[1]
Bos JM, Rietveld E, Moll HA, Steyerberg EW, Luytjes W, et al. (2007) The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach. Vaccine 25: 6922–6929.
[2]
Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E (2007) Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. Eur Respir J 30: 1158–1166.
[3]
Rietveld E, De Jonge HC, Polder JJ, Vergouwe Y, Veeze HJ, et al. (2004) Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. PIDJ 23: 523–529.
Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, et al. (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360: 588–598.
[6]
Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, et al. (2007) Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study. Pediatrics 120: e1076–e1081.
[7]
Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR (2000) Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 137: 865–870.
[8]
Weisman LE (2003) Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. PIDJ 22: S33–S37.
[9]
Welliver RC (2003) Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 143: S112–S117.
[10]
Lenney W, Boner AL, Bont L, Bush A, Carlsen KH, et al. (2009) Medicines used in respiratory diseases only seen in children. Eur Respir J 34: 531–551.
[11]
Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, et al. (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143: 532–540.
[12]
The IMpact-RSV study group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531–537.
[13]
Wang D, Cummins C, Bayliss S, Sandercock J, Burls A (2008) Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: A systematic review and economic evaluation. Health Technol Assess 12.
[14]
Wang D, Bayliss S, Meads C (2011) Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 15: iii–124.
[15]
Carbonell-Estrany X, Figueras-Aloy J, Law BJ (2004) Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. PIDJ 23: S193–S201.
[16]
Chantry CJ, Howard CR, Auinger P (2006) Full breastfeeding duration and associated decrease in respiratory tract infection in US children. Pediatrics 117: 425–432.
[17]
Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, et al. (2006) The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age. PIDJ 25: 1188–1190.
[18]
Houben ML, Bont L, Wilbrink B, Belderbos ME, Kimpen JL, et al. (2011) Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics 127: 35–41.
[19]
Lanari M, Giovannini M, Giuffre L, Marini A, Rondini G, et al. (2002) Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol 33: 458–465.
[20]
Law BJ, Langley JM, Allen U, Paes B, Lee DS, et al. (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. PIDJ 23: 806–814.
[21]
Sinha A, Madden J, Ross-Degnan D, Soumerai S, Platt R (2003) Reduced risk of neonatal respiratory infections among breastfed girls but not boys. Pediatrics 112: e303.
[22]
Ferrero F, Nascimento-Carvalho CM (2012) Clinical prediction rules and pediatric infectious diseases. Pediatr Infect Dis J 31: 628–629.
[23]
Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, et al. (2008) Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 28: 471–480 0272989X08315238 [pii];10.1177/0272989X08315238 [doi].
[24]
Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, et al. (2008) A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 9: 78.
[25]
Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361–387.
[26]
Hosmer DW, Lemeshow S (1989) Applied Logistic Regression. New York: John Wiley & Sons, Inc.
[27]
Janssen KJ, Vergouwe Y, Kalkman CJ, Grobbee DE, Moons KG (2009) A simple method to adjust clinical prediction models to local circumstances. Can J Anaesth 56: 194–201.
[28]
Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, et al. (2001) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54: 774–781.
[29]
Steyerberg EW, Neville BA, Koppert LB, Lemmens VE, Tilanus HW, et al. (2006) Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 24: 4277–4284.
[30]
Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simoes EA (2010) Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 29: 374–376.
[31]
Paes B, Steele S, Janes M, Pinelli J (2009) Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks' gestational age in Canada. Curr Med Res Opin 25: 1585–1591.
[32]
Carbonell-Estrany X, Simoes EA, Fullarton JR, Ferdynus C, Gouyon JB (2010) Validation of a model to predict hospitalization due to RSV of infants born at 33–35 weeks' gestation. J Perinat Med 38: 411–417.
[33]
Simoes EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, et al. (2011) European risk factors' model to predict hospitalization of premature infants born 33–35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med 24: 152–157.
[34]
Carbonell-Estrany X, de Mercado PL (2009) Health economics and RSV. Paediatr Respir Rev Jun; 10 Supll 1: 12–13.
[35]
Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, et al. (2012) Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J 31: e1–e8.
[36]
Lanctot KL, Masoud ST, Paes BA, Tarride JE, Chiu A, et al. (2008) The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: A Canadian-based analysis. Curr Med Res Opin 24: 3223–3237.
[37]
Prescott WA Jr, Doloresco F, Brown J, Paladino JA (2010) Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 28: 279–293.
[38]
Krilov LR, Weiner LB, Yogev R, Fergie J, Katz BZ, et al. (2009) The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. Pediatrics 124: 1682–1684.
[39]
Meissner HC, Bocchini JA Jr, Brady MT, Hall CB, Kimberlin DW, et al. (2009) The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics 124: 1676–1679.
[40]
Elhassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW (2006) Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 160: 1070–1076.
[41]
Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA (1999) Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104: 419–427.
[42]
Nuijten M, Lebmeier M, Wittenberg W (2009) Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ
